Artificial intelligence specialist wins FDA clearance for brain injury CT software

The U.S. Food and Drug Administration has granted clearance to an artificial intelligence-driven CT tool used to diagnose and track brain injuries.

Qure.ai—headquartered in New York and Mumbai—announced the news Thursday, gaining 510(k) clearance for its brain CT quantification software qER-Quant.

Clinicians using this platform can assess the severity of numerous brain conditions, including hemorrhagic stroke, hydrocephalus and traumatic brain injuries. The software can also track the progression of such injuries. 

Qure.ai now has two clearances under its belt, earning the first in June 2020.

"This FDA clearance adds quantification, outlining and measurement capabilities to Qure.ai's first clearance for triage and notification of critical brain abnormalities,” Pooja Rao, PhD, co-founder and head of R&D at the company said in a statement. “We are excited about bringing a complete suite of capabilities to clinicians who deal with critical head CT scans.”

Rao said the updated tool is based on feedback from radiologists, neurologists and emergency department physicians who wanted automatic volume measurement capabilities for their neurology scans to assess patients’ progress and aid in discharge decision making.

It’s also cleared for marketing in the EU and is being used across more than 40 healthcare sites, according to the company.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

Trimed Popup
Trimed Popup